These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 20601874)

  • 21. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
    Yin T; Miyata T
    Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Oral anticoagulation and pharmacogenetics: importance in the clinical setting].
    Benusiglio PR; Desmeules J; de Moerloose P; Dayer P
    Rev Med Suisse; 2007 Sep; 3(124):2030, 2033-4, 2036. PubMed ID: 17955831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathology consultation on warfarin pharmacogenetic testing.
    Stack G;
    Am J Clin Pathol; 2011 Jan; 135(1):13-9. PubMed ID: 21173120
    [No Abstract]   [Full Text] [Related]  

  • 24. Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen.
    Sconce EA; Kamali F
    Eur J Haematol; 2006 Dec; 77(6):457-62. PubMed ID: 17042764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetics of coumarinic oral anticoagulants.
    Manolopoulos VG; Ragia G; Tavridou A
    Pharmacogenomics; 2010 Apr; 11(4):493-6. PubMed ID: 20350128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.
    Anderson JL; Horne BD; Stevens SM; Grove AS; Barton S; Nicholas ZP; Kahn SF; May HT; Samuelson KM; Muhlestein JB; Carlquist JF;
    Circulation; 2007 Nov; 116(22):2563-70. PubMed ID: 17989110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis.
    You JH; Chan FW; Wong RS; Cheng G
    Thromb Haemost; 2004 Sep; 92(3):590-7. PubMed ID: 15351856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenomic considerations for customizing warfarin therapy in the orthopedic patient.
    Rhee S; Walsh K; Lewis D; Davis G; Smith KM
    Orthopedics; 2010 Nov; 33(11):828. PubMed ID: 21053849
    [No Abstract]   [Full Text] [Related]  

  • 30. A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity.
    Kim MJ; Huang SM; Meyer UA; Rahman A; Lesko LJ
    J Clin Pharmacol; 2009 Feb; 49(2):138-46. PubMed ID: 19179293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamic pharmacogenetic models in anticoagulation therapy.
    Bon Homme M; Reynolds KK; Valdes R; Linder MW
    Clin Lab Med; 2008 Dec; 28(4):539-52. PubMed ID: 19059061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Building individualized medicine: prevention of adverse reactions to warfarin therapy.
    Krynetskiy E; McDonnell P
    J Pharmacol Exp Ther; 2007 Aug; 322(2):427-34. PubMed ID: 17496169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin.
    Vecsler M; Loebstein R; Almog S; Kurnik D; Goldman B; Halkin H; Gak E
    Thromb Haemost; 2006 Feb; 95(2):205-11. PubMed ID: 16493479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.
    Perini JA; Struchiner CJ; Silva-Assunção E; Santana IS; Rangel F; Ojopi EB; Dias-Neto E; Suarez-Kurtz G
    Clin Pharmacol Ther; 2008 Dec; 84(6):722-8. PubMed ID: 18754001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Algorithms using clinical and genetic data (CYP2C9, VKORC1) are relevant to predict warfarin dose in patients with different INR targets.
    Le Cam-Duchez V; Frétigny M; Cailleux N; Gandelin C; Lévesque H; Borg JY
    Thromb Res; 2010 Sep; 126(3):e235-7. PubMed ID: 20569971
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacogenetics of warfarin: current status and future challenges.
    Wadelius M; Pirmohamed M
    Pharmacogenomics J; 2007 Apr; 7(2):99-111. PubMed ID: 16983400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Refining the use of warfarin through genetic testing.
    Lee SC
    Int Angiol; 2008 Aug; 27(4):271-3. PubMed ID: 18677287
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacogenomic testing for warfarin dosing: we are ready now.
    Wu AH
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1483-5. PubMed ID: 19954308
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pharmacogenetics of oral anticoagulants: individualized drug treatment for more efficacy and safety].
    Loriot MA; Beaune P
    Rev Prat; 2007 Jun; 57(12):1281-6. PubMed ID: 17717937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
    Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
    Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.